Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect

ConclusionsNivolumab is a valuable option at subsequent treatment lines for patients with advanced ESCC.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research